Kyverna Therapeutics announced the clearance of its Investigational New Drug application by the U.S. FDA for its autologous, fully human anti-CD19 chimeric antigen receptor T-cell product candidate, KYV-101, to be used for the treatment of stiff-person syndrome in Kyverna’s trial, named KYSA-8.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics announces report describing the first use of KYV-101
- Kyverna Therapeutics participates in a conference call with JPMorgan
- After Kyverna data, Oppenheimer says Cartesian ‘can exploit’ CAR-T’s ‘baggage’
- Kyverna: KYV-101 demonstrates ‘promising’ outcomes across multiple indications
- Kyverna, Cabaletta selloffs an overreaction, says Wells Fargo